Thursday, June 25, 2026
🇺🇸 FDA

QA/QC Tools · Process Validation · GMP Statistics

Process Capability Cpk Calculator

Calculate Cp, Cpk, Pp, and Ppk from mean/standard deviation or pasted measurement data. Built for pharmaceutical process validation, continued process verification, and GMP manufacturing statistics—no MDCalc equivalent exists for this workflow.

Quick Answer

Process capability indices Cp, Cpk, Pp, and Ppk compare specification limits to process variation during pharmaceutical manufacturing validation. Cp and Cpk use within-subgroup (short-term) standard deviation; Pp and Ppk use overall variation. Internal targets such as Cpk ≥ 1.33 or 1.67 reflect Six Sigma practice but are not universal regulatory requirements—acceptance criteria must be justified in the approved validation protocol per FDA 2011 Process Validation guidance and ICH Q8/Q9/Q10.

Capability formulas

Cp = (USL - LSL) / 6s   |   Cpk = min[(USL - mean) / 3s, (mean - LSL) / 3s]

Pp and Ppk use overall standard deviation when available. If only pasted individual measurements are supplied, this calculator uses the sample standard deviation for both within and overall estimates and flags the interpretation caveat.

Process Capability Calculator

Calculate Cp, Cpk, Pp, and Ppk from summary statistics or pasted measurement data.

Process statistics
Specification limits
Measurements

Paste one measurement per line or separate values with commas, spaces, or tabs. All values must use the same unit as the specification limits.

Specification limits

Capability Results

Cp
-
Cpk
-
Pp
-
Ppk
-
Calculated process statistics
Sample size-
Mean-
Sample SD-
Overall SD used for Pp/Ppk-
Nearest specification margin-
InterpretationEnter data to calculate.

How to Use the Cpk Calculator

1
Confirm the process is in a state of statistical control and the data are representative of commercial manufacturing conditions.
2
Choose Mean and SD when summary statistics are already calculated, or Pasted Measurements to compute mean and sample SD from raw data.
3
Enter lower and upper specification limits (LSL/USL) from the approved validation protocol—not action limits or development targets unless the protocol defines them as specifications.
4
Review Cp, Cpk, Pp, Ppk, and the nearest specification margin. Compare results against protocol-defined acceptance criteria and control chart evidence.
5
Document conclusions in the validation report with sampling plan rationale, SD definition, normality assessment, and link to continued process verification monitoring.

Worked Example

Tablet weight capability

Inputs: mean 100.2 mg, within-subgroup SD 0.45 mg, LSL 98.0 mg, USL 102.0 mg.

Cp: (102.0 − 98.0) / (6 × 0.45) = 4.0 / 2.7 ≈ 1.48.

Cpk: min[(102.0 − 100.2) / (3 × 0.45), (100.2 − 98.0) / (3 × 0.45)] = min(1.33, 1.63) ≈ 1.33.

Interpretation: Cpk meets a common internal 1.33 target, but the process mean sits closer to the lower limit than the upper—review centering and long-term Ppk before validation sign-off.

Cpk Interpretation Reference

Cpk range Six Sigma analogy Typical internal interpretation Validation action
< 1.0 < 3σ Low capability; high out-of-spec risk Investigate variation, centering, and control strategy before release
1.0 – 1.32 ~3σ Marginal capability Review against protocol criteria; may require improvement or risk justification
1.33 – 1.66 ~4σ Common minimum target for many CQAs Accept if protocol requires ≥ 1.33 and process stability is demonstrated
≥ 1.67 ~5σ Stricter target for critical steps Often applied to high-risk attributes; confirm with quality risk assessment

Pharma / GMP Context for QA Professionals

Process capability analysis supports Stage 2 (process qualification) and Stage 3 (continued process verification) under FDA’s 2011 Process Validation: General Principles and Practices guidance. Capability indices quantify how well a critical quality attribute (CQA) such as fill weight, assay, dissolution, or moisture fits within approved specification limits relative to observed variation—but they cannot stand alone as validation evidence.

ICH Q8(R2) pharmaceutical development, ICH Q9(R1) quality risk management, and ICH Q10 pharmaceutical quality system provide the framework for defining which attributes require capability assessment and what acceptance criteria are scientifically justified. High-risk processes identified through FMEA may warrant stricter Cpk targets; use our RPN Calculator for risk priority scoring during process design.

Capability indices apply to variable (continuous) data with two-sided or one-sided specifications. Attribute acceptance limits, cleaning residue limits, and MACO calculations use different statistical frameworks—see our Cleaning Validation Limit Calculator for PDE/ADE-based carryover limits. Link capability results to control charts, batch release data, and periodic CPV reviews per EU GMP Annex 15 and site SOPs.

Limitations and Validation Caveats

  • Capability indices assume a stable, representative process. Review control charts, shifts, trends, and special-cause signals before relying on Cp or Cpk.
  • Specification limits must be scientifically justified. Do not use action limits, alert limits, or development targets as substitutes unless the protocol defines them that way.
  • Non-normal data, censored results, small samples, multiple lots, or mixed equipment trains may require transformation, tolerance intervals, or alternative methods.
  • Cp/Cpk cannot replace process qualification, cleaning validation, continued process verification, deviation review, or quality risk management.

Sources and Regulatory Context

Frequently Asked Questions

Cp measures process potential: specification width divided by six times within-subgroup standard deviation, ignoring centering. Cpk adjusts for centering using the distance from the mean to the nearest specification limit. Pp and Ppk are performance indices that use overall (long-term) standard deviation instead of within-subgroup variation. In pharmaceutical validation reports, the SD definition must match the approved sampling plan and SOP.
Cpk ≥ 1.33 is a widely cited internal minimum for many manufacturing processes, corresponding roughly to four sigma capability if the process is centered and normally distributed. Cpk ≥ 1.67 is a stricter target often applied to critical quality attributes or high-risk steps. Neither value is a universal FDA or EMA regulatory requirement; acceptance criteria must be risk-based and documented in the validation protocol.
In Six Sigma terminology, Cpk of 1.0 approximates three sigma capability, 1.33 approximates four sigma, and 1.67 approximates five sigma when the process is stable and normally distributed. Pharmaceutical sites often adopt these benchmarks from Six Sigma programs, but regulatory acceptance depends on product risk, control strategy, and scientific rationale—not the sigma label alone.
Within-subgroup standard deviation estimates short-term, common-cause variation—often from rational subgroups such as consecutive units within a batch or fill head. Overall standard deviation includes batch-to-batch, shift, and long-term sources of variation. Cp/Cpk use within-subgroup SD; Pp/Ppk use overall SD. A large gap between Cpk and Ppk signals that long-term variation exceeds short-term expectations.
Process validation (Stage 1–3 per FDA 2011 guidance) establishes that a process consistently produces acceptable product through design, qualification, and initial verification. Continued process verification is ongoing monitoring to confirm the process remains in a state of control. Capability indices may appear in validation reports and CPV trending, but CPV also requires control charts, batch review, deviation analysis, and periodic re-evaluation.
FDA’s 2011 Process Validation guidance emphasizes a lifecycle approach—process design, process qualification, and continued process verification—grounded in scientific understanding and quality risk management. Capability statistics support but do not replace documented evidence of reproducibility, control strategy, and data integrity. Any Cpk acceptance criterion must be justified in the validation protocol and linked to critical quality attributes.
Cpk assumes a stable, normally distributed process with correctly defined specification limits. It can mislead when data are skewed or censored, when special causes are present, when specifications are not scientifically justified, when mixed lots or equipment trains are combined, or when sample size is too small. Always review control charts and batch history before relying on a single capability number.
There is no single regulatory sample size. Validation protocols often specify minimum subgroup counts and total measurements based on process risk, attribute criticality, and statistical power. Small samples produce unstable Cpk estimates with wide confidence intervals. Representative data from a demonstrated stable process, combined with control chart evidence, is required before drawing validation conclusions.
When only an upper or lower specification limit applies, capability uses the distance from the process mean to that limit divided by three times the standard deviation—equivalent to a one-sided Cpk or Ppk. Cp is not defined for one-sided specs because there is no specification width. Cleaning limits, assay maximums, and impurity caps often use one-sided limits; confirm the calculation matches the approved SOP.
Cp and Cpk require variable (continuous) data and specification limits in the same measurement units. Attribute data—pass/fail, defect counts, or categorical results—use different methods such as defect rates, fraction nonconforming, or Poisson/binomial models. Applying Cpk to attribute acceptance limits is statistically invalid; use the method defined in the validation protocol for attribute critical quality attributes.
No. Capability indices are statistical summaries only. Pharmaceutical process validation also requires documented process design, equipment qualification, analytical method validation, cleaning validation where applicable, control strategy, deviation review, data integrity controls, and continued process verification per FDA and EU GMP expectations.
Classical Cp/Cpk interpretation assumes approximate normality. Non-normal or bounded data—common for dissolution, moisture, or near-zero impurity results—may require transformation, tolerance intervals, or non-parametric methods specified in the validation protocol. Report the normality assessment and alternative method when standard capability indices are not appropriate.

Related Tools

RPN RPN Calculator MACO Cleaning Validation Limit GMP GMP Checklist Generator Audit Audit Readiness Checklist ISO Cleanroom Classification

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.